chrisvoncsefalvay/vaers-outcomes huggingface dataset:
inflammation symptoms- left clavicle pain; general neck pain; area above left ear hurts when touched; migraine on 2nd day; This is a spontaneous report from a non contactable consumer, the patient. A 38-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via an unspecified route of administration in the left arm on 17Mar2021 at 16:00 (at the age of 38-years-old), as a single dose for COVID-19 immunisation. Medical history included migraine, hypoglycemia, and obese with chronic inflammation issues like neck pain . The patient had allergies to dog and mold as well as severe seasonal allergies, also she had no known drug allergy. The concomitant medications within two weeks included cetirizine hydrochloride (ZYRTEC), fluticasone propionate (FLONASE), ibuprofen (MANUFACTURER UNKNOWN) for unknown indication. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, it was unknown if the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient experienced migraine on 20Mar2021, inflammation symptoms-left clavicle pain (shoulder pain), general neck pain, area above left ear hurts when touched (ear pain) on 21Mar2021 at 20.00. It was 4-day delayed reaction. The patient was obese with chronic inflammation issues like neck pain. The notable pain on end of clavicle closest to arm and horrific pain above ear on head was new as well as the migraine not being from hormonal change as they were typical. The patient did not receive any treatment for the reported events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of shoulder pain, neck pain, migraine and ear pain were not resolved at the time of this report.   Information about lot/batch number cannot be obtained. No further information is expected.
There was no adverse reaction, vaccine expired on 08/31/2021 and vaccine was administered on 09/17/2021.; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (There was no adverse reaction, vaccine expired on 08/31/2021 and vaccine was administered on 09/17/2021.) in a 48-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037A21B) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Sep-2021 at 4:09 PM, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Sep-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (There was no adverse reaction, vaccine expired on 08/31/2021 and vaccine was administered on 09/17/2021.). On 17-Sep-2021, EXPIRED PRODUCT ADMINISTERED (There was no adverse reaction, vaccine expired on 08/31/2021 and vaccine was administered on 09/17/2021.) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered EXPIRED PRODUCT ADMINISTERED (There was no adverse reaction, vaccine expired on 08/31/2021 and vaccine was administered on 09/17/2021.) to be not related.    No Concomitant medications were reported.  No treatment medications were reported.  It was reported that this lot number expiration date was not extended.   This case was linked to MOD-2021-328706 (Patient Link).
MOTOR PARESIS OF BILATERAL LOWER EXTREMITIES AND BOTH HANDS- LIMITIED HAND GRIP.
nausea, headache, fever, chills, diarrhea, joint pain, redness at injection sites
AFTER THE 2ND DOSE I HAD A LARGE FLOATER APPEAR IN MY LEFT EYE.
approx 3PM mom states took child home & had nap;given APAP a/nap;awoke from nap difficult to arouse, limp, heavy eyelids;called clinic-to clinic 530PM;PEARL-muscle  tone WNL;
metallic taste in the mouth; tiredness; This spontaneous case was reported by a consumer and describes the occurrence of DYSGEUSIA (metallic taste in the mouth) and FATIGUE (tiredness) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046A21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event. Concomitant products included DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Allergy.    On 24-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Mar-2021, the patient experienced DYSGEUSIA (metallic taste in the mouth) and FATIGUE (tiredness). At the time of the report, DYSGEUSIA (metallic taste in the mouth) and FATIGUE (tiredness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Other concomitant medications include Pseudo fen at AM for allergies.
Joints in my legs, knees, ankles, jaw bone, ears, armpits.....the pain in my ankles, armpits, jawbone and wars have subsided,  pain in my knees are still there...not as bad as the 1st day. Mostly my right knee since I had knee replacement in Sept 2020
Patient received J+J vaccination on 5/15/2021 then received Pfizer vaccine as documented in this report.
MYELITIS; KIDNEY FAILURE; This spontaneous report received from a consumer concerned a 52 year old male. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 203A21A, and expiry: unknown) dose was not reported, 1 total administered at left arm on 01-JUN-2021 for prophylactic vaccination. Age at time of vaccination 52 years old. No concomitant medications were reported. On 08-JUN-2021, a week after vaccination, the patient had been suffering from severe pain and that his muscles were being eaten away that had prompted his hospitalization more than six times with symptoms ranging from pain to collapse. The patient was diagnosed with myelitis. He was hospitalized on an unspecified date and for unspecified days, it was unknown whether the patient was discharged from the hospital or not. On 11-MAY-2022, the patient's kidney function began to deteriorate. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from myelitis, and kidney failure. This report was serious (Hospitalization Caused / Prolonged, Other Medically Important Condition, and Disability Or Permanent Damage).; Sender's Comments: V0: 20220537814-covid-19 vaccine ad26.cov2.s -Myelitis, kidney failure. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s). Therefore, this event(s) is considered unassessable.
Shingles; This spontaneous case was reported by a consumer and describes the occurrence of Shingles in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced Shingles. At the time of the report, Shingles outcome was unknown. Not Provided.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant product use was reported.  No treatment information was provided.
Started off as a localized reaction where the injection was given then the redness and pain started radiating towards the elbow.
flu vaccine is more painful; Initial information was received on 11-Nov-2022 regarding an unsolicited valid non-serious case received from a patient.  This case involves Adult female patient who reported flu vaccine is more painful while receiving vaccine Influenza vaccine.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect Influenza vaccine (produced by unknown manufacturer) (with unknown strength, dose, route, administration site, lot number and expiration date) for Prophylactic vaccination.  On an unknown date the patient reported flu vaccine is more painful (Vaccination site pain) (unknown latency) following the administration of Influenza vaccine.  It was reported that: Consumer states the pain with injection is from alcohol wipe and needle going in skin. She states by the time she removes the needle there is no more pain. She states the flu vaccine is more painful. She is not going to respond to paperwork she received.  Action taken: Not applicable.  Corrective treatment: Not reported.  Outcome: Unknown.
Swollen face, especially swelling around eyes, swollen glands, infection in gland, fever and chills.
Expired VAQTA vaccine was administered; This spontaneous report has been received from a consumer referring to a patient of unknown age. Information regarding the patient's medical history, drug reactions or allergies, concurrent conditions and concomitant medications was not provided.     On 27-AUG-2020, the patient was vaccinated with an expired dose of hepatitis a vaccine, inactivated (VAQTA) lot # S021092 (strength, indication, dose, route, frequency, and anatomical location were not provided) for prophylaxis (expired product administered). combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. ; devicelotnumber: S021092; expirationdate: 18-MAY-2020; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability
I arrived home after the 15 minute check. I went into the restroom, and started to feel nausea with dizziness. I felt like I was going to pass out. Then my head started to hurt, and the room was spinning. I had no appetite, and was very pale. My symptpms lasted till Friday afternoon. My stomach didnt feel right for days.  Johnson & Johnson vaccine
reaction after the dose; he had no antibodies for the virus; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (reaction after the dose) and DRUG INEFFECTIVE (he had no antibodies for the virus) in an 87-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Chronic lymphocytic leukaemia.   In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (reaction after the dose) and DRUG INEFFECTIVE (he had no antibodies for the virus). At the time of the report, VACCINATION COMPLICATION (reaction after the dose) and DRUG INEFFECTIVE (he had no antibodies for the virus) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: low (Low) small temperature. On an unknown date, SARS-CoV-2 antibody test: negative (Negative) no antibodies for the virus.    Concomitant drug was not reported.  Treatment medication was not reported.
Pt came up to pharmacy window 40 minutes after receiving vaccine stating she was feeling lightheaded, had some slight tingling in her left arm and side of her face.  Pt stated she wasn't feeling well. Patient did not have signs/symptoms of an allergic reaction. Patients condition maintained same level and patient left the pharmacy area on her own.  Patient was advised to seek medical treatment if she had any difficulty breathing or tightness in her chest or her condition worsened.
Dizziness, nausea, localized pressure in head (R lateral) that is waxing and waning. Observed 15 min. Water/crackers given. Stable and released.
This case was reported by a healthcare professional and described the occurrence of hypoglycemia in a 64-year-old female subject who was vaccinated with FLULAVAL (GlaxoSmithKline). Concurrent medical conditions included diabetes controlled by diet and heart disease. There were no concurrent medications. On the morning of 7 October 2008 the subject received unspecified dose of FLULAVAL at 0.5 ml. On 7 October 2008, about 1 hour after vaccination with FLULAVAL, the subject experienced hypoglycemia and sleepiness. This case was assessed as medically serious by GSK. Product complaint was reported. At the time of reporting the outcome of the events was unspecified. The reporter stated that they gave 20 doses of FLULAVAL in the morning and three subjects reported hypoglycemia.
pt recv vax 24DEC97 & 26DEC97 pt exp a gen feeling of achiness & weakness & had red non-raised skin in a circular pattern around the site of inj;
raised welts on her left arm from shoulder to elbow that went under her arm/rash; arm was red; arm was itchy; arm was warm; raised welts on her left arm from shoulder to elbow that went under her arm/rash; arm was sore; arm was swollen; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE PAIN (arm was sore), VACCINATION SITE SWELLING (arm was swollen), VACCINATION SITE ERYTHEMA (arm was red), VACCINATION SITE PRURITUS (arm was itchy) and VACCINATION SITE WARMTH (arm was warm) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event.    On 22-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Feb-2021, the patient experienced VACCINATION SITE PAIN (arm was sore) and VACCINATION SITE SWELLING (arm was swollen). On 01-Mar-2021, the patient experienced VACCINATION SITE ERYTHEMA (arm was red), VACCINATION SITE PRURITUS (arm was itchy), VACCINATION SITE WARMTH (arm was warm) and VACCINATION SITE URTICARIA (raised welts on her left arm from shoulder to elbow that went under her arm/rash). On an unknown date, the patient experienced RASH (raised welts on her left arm from shoulder to elbow that went under her arm/rash). On 25-Feb-2021, VACCINATION SITE PAIN (arm was sore) and VACCINATION SITE SWELLING (arm was swollen) had resolved. On 05-Mar-2021, VACCINATION SITE ERYTHEMA (arm was red), VACCINATION SITE PRURITUS (arm was itchy), VACCINATION SITE WARMTH (arm was warm) and VACCINATION SITE URTICARIA (raised welts on her left arm from shoulder to elbow that went under her arm/rash) had resolved. At the time of the report, RASH (raised welts on her left arm from shoulder to elbow that went under her arm/rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       no concomitant medications were provided treatment medications includes steroid shot sulfamethoxazole-trimethoprim 800/160mg   This case was linked to US-MODERNATX, INC.-MOD-2021-060480 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-060480:friend case
Patient received second dose of Pfizer vaccine on 6/10/21. 12 hours after administration she developed fever (Tmax 103F), chills, myalgia. On 6/13/2021, she developed vaginal mucositis prompting hospital admission for evaluation and pain management. She was originally discharged with supportive care (Tylenol/ Motrin for pain) and if needed triamcinolone 0.1% cream. Per chart check, she was seen by PCP six days later and had not yet started triamcinolone cream and still in pain. PCP prescribed topical clobetasol, and oral prednisone 20mg BID for 5 days based on dermatology recommendations for treatment of Lipshutz ulcers.
03/08/2023 I woke up with an excruciating back pain and noticed a rash that was burning and itching in my lower back. I was diagnosed with Shingles and prescribed VALTREX; MOTRIN 800 mg; OTC TYLENOL every 8 hours and lidocaine topical cream.
40 patients administered with vaccines that have undergone temperature excursion; 40 patients administered with vaccines that have undergone temperature excursion; This spontaneous case was reported by a medical assistant and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (40 patients administered with vaccines that have undergone temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (40 patients administered with vaccines that have undergone temperature excursion) in a 35-year-old patient of an unknown gender who received mRNA-1273 (Spikevax) for COVID-19 vaccination.     No Medical History information was reported.   On 31-Jan-2022, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 28-Feb-2022, received second dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (40 patients administered with vaccines that have undergone temperature excursion). an unknown date, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (40 patients administered with vaccines that have undergone temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (40 patients administered with vaccines that have undergone temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (40 patients administered with vaccines that have undergone temperature excursion) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was provided by the reporter.  Only lot number 059H21A, thawed on 28-Jan-2022 was affected with expiration date 27-Mar-2022. On 28-Jan-2022 Maximum or minimum temperatures reached range was positive 34.7 degree Fahrenheit to positive 41.2 degree Fahrenheit, on 30-Jan-2022 temperature range was positive 34.7 degree Fahrenheit to positive 41.2 degree Fahrenheit which occurred approximately for 48 hours, on 31-Jan-2022 temperature range was positive 34.7 degree Fahrenheit to positive 41.2 degree Fahrenheit for 12 hours and on 04-Feb-2022 temperature range was positive 35.2 degree Fahrenheit to positive 41.7 degree Fahrenheit for 12 hours.  No patient reported any adverse event. No treatment medication was provided by the reporter.
Patient reported generalized rash to all extremities, torso and facial area approx. 3 hrs. after receiving vaccine. Offered and accepted 50 mg Benadryl. No SOA or hives
Two days after first shot I developed intermittent ringing in left ear. After second shot I now have a constant ringing in my left ear. And every few days there is ringing in both ears. But that goes away. My doctor says this is not related to the shot and sent me to get a hearing test. It's scheduled for next month.
Severe neck stiffness that were followed by migraines and soreness in back of neck at Days 4, 5 and 6.
itchy sensation; Rash at injection site/Rectangular shape rash under injection site; Swollen lymph node on same side as injection; This is a spontaneous report from a contactable consumer (patient). A 33-year-old non-pregnant female patient received bnt162b2 (Lot Number: EN6206), via an unspecified route of administration, administered in left arm on 10Mar2021 10:00 AM (at the age of 33 years old) as single dose for covid-19 immunization. Medical history included juvenile asthma, patient had allergy coconut. Concomitant medication in two weeks included ethinylestradiol/ levonorgestrel (JOLESSA, contraceptive pills). The patient had not COVID prior vaccination and did not have COVID tested post vaccination. The patient had other vaccine in four weeks, included unspecified Pfizer vaccine (Lot number: EN9809) on 17Feb2021. The patient experienced rash at injection site day after 11Mar2021 (12Mar2021). Swollen lymph node on same side as injection on 11Mar2021 at 07:00. Rectangular shape rash under injection site and itchy sensation on 13Mar2021 upon waking. Second rash is approximately 1" tall by 2.5" wide. No treatment for events. The outcome of events was not recovered.  No follow up attempts are possible. No further information is expected.
Soreness at the injection site; This is a spontaneous report from a contactable other health professional, the patient.   A 46-years-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: EN5318) via an unspecified route of administration, administered in left arm on 26Jan2021 12:00 pm as unknown, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient experienced soreness at the injection site on 26Jan2021 15:00. The patient was not pregnant. The patient did not receive any other vaccine in four weeks and did not receive any other medications in two weeks. The patient not had covid prior vaccination. The patient had not been tested for COVID-19 post vaccination. No treatment was received for the event. The outcome of event was recovered.  Follow-up attempts are completed. No further information is expected.
Pt received DTaP instead of TD 2/27/2006. Pt presented in clinic 3/6/06 for unrelated issue. Pt reports small amt of swelling, soreness at site which resolved in 2-3 days.
Patient received the Pfizer-BioNTech COVID-19 Vaccine EUA at 1931. Then started experiencing lip tingling at 1942. Benadryl 50mg given at 1944, tingling resolved at1950.  Reports dry eyes but otherwise ok at 1956 and left the vaccine clinic.
On a night following the vaccination, pt developed fever and generalized pain and tenderness. Fever resolved but swelling at injection site persisted, currently with symptom.
Patient experienced an erythematous patches encompassing the entire left upper extremity at its peak with reported 103F fever and malaise. Seven days after administration,  a 3cm tender erythematous indurated patch persists over injection site.
Information has been received on 05-FEB-2019 from a lawyer and a female patient regarding a case in litigation. The patient was inoculated with ZOSTAVAX (lot number and expiration not reported) in 2009 at a medical center, as recommended for routine adult health maintenance for the prevention of shingles. The vaccine did not prevent shingles as intended, but rather caused the patient to contract a persistent strain of herpes zoster. The patient was treated at a medical center for a blistering vesicular outbreak which was diagnosed as herpes zoster or shingles. As a direct and proximate result of the vaccine ZOSTAVAX and/or despite receiving ZOSTAVAX for prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
Client reports "seizure like" activity; states that she went to bed feeling fine, but woke up out of no where at 5:00 with a horrible headache and shaking. States that she passed out and woke up approximately 5 minutes later with a fever of 102.7 degrees F. States that she was really weak, and fatigued. Denies any issues/side effects with previous covid-19 vaccinations.